Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Hs 578T | TNBC | Basal B | PD173074 | FGFR1/3 | RTK | 2.67 | uM | 7472.1 | 2.7719 | 4.0030 | 1.1120 | |
HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7450.091 | 2.8027 | 4.3776 | 1.0419 | |
HCC1806 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7450.091 | 2.8858 | 4.5306 | 1.0419 | |
Hs 578T | TNBC | Basal B | Trichostatin A | HDAC | HDAC | 0.064 | uM | 7472.065 | 2.9067 | 4.9213 | 0.9830 | |
LY2 | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7477.084 | 3.0073 | 5.3920 | 0.9476 | |
LY2 | HR+ | Luminal | PS-1145 | IKK | NFKB | 379 | uM | 7477.065 | 3.5926 | 9.1125 | 0.7891 | |
LY2 | HR+ | Luminal | PS-1145 | IKK | NFKB | 1890 | uM | 7477.065 | 4.1296 | 11.0648 | 0.7891 |